Serum Transthyretin as a Biomarker of Treatment Response in ATTR Cardiomyopathy.
作者信息
Regan Jessica A, Kittleson Michelle M, Khouri Michel G, Ruberg Frederick L, Selvaraj Senthil
机构信息
Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Department of Cardiology, Smidt Heart Institute, Los Angeles, California, USA.
出版信息
J Am Coll Cardiol. 2025 May 27;85(20):1924-1926. doi: 10.1016/j.jacc.2025.04.014.
Abstract
摘要
相似文献
1
Serum Transthyretin as a Biomarker of Treatment Response in ATTR Cardiomyopathy.
J Am Coll Cardiol. 2025 May 27;85(20):1924-1926. doi: 10.1016/j.jacc.2025.04.014.
2
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy.
J Am Coll Cardiol. 2025 May 27;85(20):1911-1923. doi: 10.1016/j.jacc.2025.03.542.
3
Differential Binding Affinities and Kinetics of Transthyretin Stabilizers.
J Cardiovasc Pharmacol. 2025 Jun 5;86(2):204-9. doi: 10.1097/FJC.0000000000001726.
4
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.
J Am Coll Cardiol. 2025 Mar 18;85(10):1003-1014. doi: 10.1016/j.jacc.2024.11.042.
5
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.
J Am Coll Cardiol. 2019 Jul 23;74(3):285-295. doi: 10.1016/j.jacc.2019.03.012. Epub 2019 Mar 15.
6
Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation.
Kardiol Pol. 2025;83(2):121-137. doi: 10.33963/v.phj.104054. Epub 2025 Jan 7.
7
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.
Circulation. 2025 Mar 4;151(9):601-611. doi: 10.1161/CIRCULATIONAHA.124.072771. Epub 2024 Nov 18.
8
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy.
JACC CardioOncol. 2021 Oct 19;3(4):580-586. doi: 10.1016/j.jaccao.2021.08.007. eCollection 2021 Oct.
9
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.
N Engl J Med. 2024 Jan 11;390(2):132-142. doi: 10.1056/NEJMoa2305434.
10
Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy.
Glob Cardiol Sci Pract. 2023 Jan 30;2023(1):e202304. doi: 10.21542/gcsp.2023.4.
本文引用的文献
1
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy.
J Am Coll Cardiol. 2025 May 27;85(20):1911-1923. doi: 10.1016/j.jacc.2025.03.542.
2
Differential Association of Transthyretin Stability with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy: The SCAN-MP Study.
JACC Heart Fail. 2024 Dec;12(12):2113-2115. doi: 10.1016/j.jchf.2024.06.014. Epub 2024 Aug 7.
3
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.
N Engl J Med. 2024 Jan 11;390(2):132-142. doi: 10.1056/NEJMoa2305434.
4
Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy.
JACC CardioOncol. 2021 Oct 19;3(4):580-586. doi: 10.1016/j.jaccao.2021.08.007. eCollection 2021 Oct.
5
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
Eur J Heart Fail. 2021 Feb;23(2):277-285. doi: 10.1002/ejhf.2027. Epub 2020 Nov 12.
6
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.
J Am Coll Cardiol. 2019 Jul 23;74(3):285-295. doi: 10.1016/j.jacc.2019.03.012. Epub 2019 Mar 15.
Zotero 插件